DSS · Insider Trading
DSS, Inc.
Every open-market purchase and sale reported by DSS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-08 | Heng Fai Ambrose Chan | Director | Sell | −21,852 | −$17.92K |
| 2026-07-09 | Alset Inc. | 10%+ Owner | J | +49,662,165 deriv. | — |
| 2025-09-02 | Heng Fai Ambrose Chan | Director | Sell | +130,679 | +$176.09K |
| 2025-09-02 | Alset Inc. | 10%+ Owner | J | — | — |
| 2025-08-22 | Heng Fai Ambrose Chan | Director | J | +1,162,790 deriv. | — |
| 2025-02-10 | Heng Fai Ambrose Chan | Director | A | +1,000,000 | — |
| 2024-12-12 | Heng Fai Ambrose Chan | Director | Buy | +2,051,492 | +$2.00M |
| 2024-01-02 | William Wai Leung Wu | Director | Sell | −151,020 | −$19.78K |
| 2024-01-02 | Heng Fai Ambrose Chan | Director | Buy | +672,173 | +$98.14K |
| 2023-04-18 | Frank D Heuszel | Chief Executive Officer | A | +1,247,078 | +$270.37K |
| 2022-12-14 | Heng Fai Ambrose Chan | Director | Buy | +334,921 | +$75.89K |
| 2022-12-13 | Heng Fai Ambrose Chan | Director | Buy | +51,385 | +$9.92K |
| 2022-07-14 | Heng Fai Ambrose Chan | Director | J | +64,098,531 | — |
| 2022-07-11 | Heng Fai Ambrose Chan | Director | Buy | +35,141,896 | — |
| 2022-06-21 | William Wai Leung Wu | Director | Buy | +10,000 | +$3.79K |
| 2022-06-14 | William Wai Leung Wu | Director | Buy | +140,000 | +$57.38K |
| 2022-06-01 | Frank D Heuszel | Chief Executive Officer | A | +63,205 | +$28.44K |
| 2022-05-27 | Heng Fai Ambrose Chan | Director | A | +15,389,995 | — |
| 2022-04-19 | Heng Fai Ambrose Chan | Director | A | +894,084 | — |
| 2022-03-10 | Heng Fai Ambrose Chan | Director | Buy | +7,973,754 | +$3.04M |
| 2021-09-10 | Global BioMedical Pte. Ltd. | — | — | — | — |
| 2021-09-10 | Alset EHome International Inc. | 10%+ Owner | Buy | +24,311,182 | +$30.00M |
| 2021-06-23 | Heng Fai Ambrose Chan | Director | C | +2,240,340 | — |
| 2021-06-17 | Heng Fai Ambrose Chan | Director | Buy | +1,555,000 | +$2.64M |
| 2021-05-27 | Heng Fai Ambrose Chan | Director | C | +10,900,000 | — |
| 2020-10-23 | Global BioMedical Pte. Ltd. | 10%+ Owner | C | +1,325,000 | — |
| 2020-08-25 | Heng Fai Ambrose Chan | Director | J | +483,334 | +$3.13M |
| 2020-03-05 | Heng Fai Ambrose Chan | Director | A | +11,111,112 | +$2.00M |
| 2020-02-27 | Heng Fai Ambrose Chan | Director | A | +11,111,111 | +$2.00M |
| 2020-02-21 | Heng Fai Ambrose Chan | Director | A | +349,917 | — |
| 2019-11-05 | Heng Fai Ambrose Chan | Director | Buy | +6,000,000 | +$1.82M |
| 2019-07-25 | Wah Wai Lo | Director | A | +40,767 | — |
| 2019-07-24 | Daniel DelGiorno | Director | A | +40,767 | — |
| 2019-07-24 | Joseph L. Sanders | Director | A | +30,575 | — |
| 2019-07-24 | Frank D Heuszel | Chief Executive Officer | A | +74,770 | — |
| 2019-07-24 | John Thatch | Director | A | +30,575 | — |
| 2019-07-24 | Stanley V. Grisham | Director | A | +30,575 | — |
| 2019-07-24 | Jason Grady | Chief Operating Officer | A | +74,770 | — |
| 2019-07-24 | Heng Fai Ambrose Chan | Director | A | +74,770 | — |
| 2019-07-24 | Pamela Avallone | Director | A | +30,575 | — |
| 2019-07-24 | Brett L Scott | Director | A | +30,575 | — |
| 2019-06-10 | Joseph L. Sanders | Director | Buy | +1,181 | +$562 |
| 2019-06-10 | Heng Fai Ambrose Chan | Director | Buy | +2,000,000 | +$1.00M |
| 2019-05-21 | Joseph L. Sanders | Director | Buy | +3,181 | +$3.34K |
| 2019-03-26 | Heng Fai Ambrose Chan | Director | C | +446,428 | +$500.00K |
| 2019-03-06 | Daniel DelGiorno | Director | J | +130,435 | +$150.00K |
| 2019-02-20 | Heng Fai Ambrose Chan | Director | Buy | — | — |
| 2018-12-18 | Heng Fai Ambrose Chan | Director | Buy | +612,245 | +$600.00K |
| 2018-07-05 | Heng Fai Ambrose Chan | Director | Buy | +214,286 | +$300.00K |
| 2018-04-16 | Robert B Fagenson | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Heng Fai Ambrose Chan | Director | 2,034,922 | $1.02M |
| Alset Inc. | 10%+ Owner | 1,109,588 | $554.79K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DSS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.